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yahoo.com.cn (J. Zhu).There is increasing evidence that microRNAs (miRNAs) play important roles in cell proliferation,
apoptosis and differentiation that accompany inﬂammatory responses. However, whether microR-
NAs are associated with DC immuno-inﬂammatory responses with oxidized low density lipoprotein
(oxLDL) stimulation is not yet known. Our study aims to explore the link of miRNAs with lipid-
overload and immuno-inﬂammatory mechanism for atherosclerosis. In DCs transfected with
microRNA-29a mimics or inhibitors, we showed that microRNA-29a plays an important role in
proinﬂammatory cytokine secretion and scavenger receptor expression upon oxLDL-treatment.
Furthermore, we suggest an additional explanation for the mechanism of microRNA-29a regulation
of its functional target, lipoprotein lipase. We conclude that microRNA-29a could regulate pro-
inﬂammatory cytokine secretion and scavenger receptor expression by targeting lipoprotein lipase
in oxLDL-stimulated dendritic cells.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis is currently the leading cause of humanmorbid-
ity and mortality in developed countries, and has been established
as a chronic inﬂammatory disease [1]. Oxidized low-density lipo-
proteins (oxLDLs) remain the most important risk factor for athero-
sclerosis. Recently, the immuno-inﬂammatory mechanisms of
atherosclerosis have gained tremendous interest and the process
has been recognized as a complex interplay between modiﬁed lip-
ids, different cells of the immune system, endothelial cells, and
smooth muscle cells [2]. Aside from the well-known cell types such
as monocytes, T cells, and B cells, the unexpected roles of dendritic
cells (DCs) in atherosclerosis have recently been discovered [3].
DCs, specialized antigen-presenting cells, are central to the regula-
tion of immunity because they are at the interface of the innatechemical Societies. Published by E
RNA; OxLDL, oxidized low
, interleukin; LPL, lipoprotein
poprotein receptor-1; UTR,
(H. Yan), +86 21 87236700
(H. Yan), ting010151452@and adaptive immune systems. DCs also play an important role
in this activation and affect the initiation and progression of ath-
erosclerosis, either pro-atherogenically or anti-atherogenically
[4]. However, despite ongoing research regarding the immune-
inﬂammatory mechanisms in atherosclerosis, the intracellular
molecular events that induce and regulate the activation have
yet to be elucidated.
MicroRNAs (miRNAs), a novel class of short (22 nucleotides)
non-coding RNAs, have been identiﬁed as important post-
transcriptional inhibitors of gene expression by base pairing with
the 30 untranslated regions (UTRs) of mRNAs and promoting mRNA
stability [5,6]. miRNAs are implicated in various physiologic and
pathologic processes [7,8], including cardiogenesis, hematopoietic
lineage differentiation, and oncogenesis.
Accumulating evidence suggest that miRNAs also play an
important role in cardiovascular disease [9–15]. The MiR-29 fam-
ily, predicted to function as inhibitors of numerous mRNAs in-
volved in extracellular matrix (ECM) production and ﬁbrosis, are
pathologically associated with tumor and cardiac ﬁbrosis through
the regulation of collagens [16,17]. The expression of miR-29a is
downregulated after myocardial infarction [18]. Holmstrom et al.
[19] revealed the differential expression of miR-29a in mature
DCs relative to immature DCs. In this study, the increased expres-
sion of miR-29a in oxLDL-stimulated DCs is ﬁrst established, inlsevier B.V. All rights reserved.
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(LPL) and their functional roles in the lipid uptake and pro-
inﬂammatory cytokine secretion by oxLDL-stimulated DCs were
determined. Furthermore, miR-29a is shown to decrease the pro-
inﬂammatory cytokine secretion and enhance scavenger receptors
expression efﬁciently by targeting LPL, evidence that regulation of
LPL is associated with miR-29a in DCs is also provided.2. Materials and methods
The investigation conformed with the principles outlined in the
Declaration of Helsinki for the use of human blood and was
approved by the Ethics Committee of Experimental Research of
Zhejiang University.
2.1. Human primary peripheral blood DC culture
Peripheral human blood was obtained from healthy donors.
Mononuclear cells were isolated by centrifugation through a
Ficoll-isopaque (Sigma) density gradient [20]. To obtain the
monocytes, the mononuclear cells were allowed to adhere to 6-
wells plates with 5% autologous serum for 2 h at 37 C, in a 5%
CO2 incubator. Non-adherent cells were removed and the adher-
ent cells (monocytes) were co-cultured with with 1000 units/ml
granulocyte GM-CSF and 1000 units/ml interleukin-4 for 5–7 days
to obtain the immature DCs, monocytes were cultured in a
complete medium (RPMI 1640 with 10% fetal calf serum). OxLDL
(30 ug/ml) was added at day 6 and cells were harvested at
day 7.
2.2. Small RNA transfection by electroporation treatment
Pre-miR™ precursor molecules for miR-29a, anti-miR™ inhibi-
tor for miR-29a were obtained from Dharmacon. SiLPL and siNS
(not signiﬁcant) duplex were synthesized by Dharmacon RNAi
Technologies. DCs were harvested and resuspended in Opti-MEM
(Invitrogen Life Technologies) at a concentration of 4  107 cells/
ml. Next, 7.5 ug miRNA inhibitor/mimic and siRNA (Dharmacon)
were transferred to a 4-mm cuvette (Peqlab Biotechnologie) and
ﬁlled to a ﬁnal volume of 100 ul with Opti-MEM. Cell suspension
was added and immediately pulsed in a Gene Pulser II apparatus
(Bio-Rad) at 300 V, 150 uF, and 100 ohms. To conﬁrm the efﬁciency
of transfection, the same amount of Cy3-labeled negative control
was also transfected and the efﬁciency of miR-29a overexpression
and inhibition were at least 90%.
2.3. HPLC analysis of lipid levels
DCs were transfected with miRNA mimic and inhibitor, oxLDL
was added 6 h after transfection, and cells were further incubated
for 24 h. The sterol analyses were performed using an HPLC system
(model 2790, controlled with Empower Pro software; Waters
Corp., Milford, MA). Sterols were detected using a photodiode array
detector equipped with a 4-lL cell (model 996; Waters Corp.).
Analysis of cholesterol and cholesteryl esters was performed after
elution with acetonitrile-isopropanol 30:70 (v/v) [21] and detec-
tion by absorbance at 210 nm.
2.4. ELISA assays of inﬂammatory markers and LPL expression
DCs that have undergone 24 h incubation with oxLDL were used
for ELISA. Culture supernatants were analyzed to determine the
presence of tumor necrosis factor-a (TNF-a), IL-6, LPL using Sand-
wich Enzyme Immunoassay kits (RD) according to the manufac-
turer’s instructions.2.5. Cloning of 30 UTR of LPL mRNA and reporter gene assay
The 293T were cotransfected with p-LPL UTR miRNA luciferase
reporter vector and miR-29a mimic/inhibitor using lipofectamine
2000 (Invitrogen). Cells were also transformed with the PGL3-con-
trol vector, which is useful for monitoring transfection efﬁciency.
MiRNA mimic/inhibitor negative, an miRNA non-homologous to
the human genome, was used as a control. All cells were also trans-
fected with pRL-TK (Promega) for normalization control. After
24 h, ﬁreﬂy luciferase activities were determined using the dual-
luciferase reporter assay system. Relative reporter activity was ob-
tained by normalization to the Renilla control. The ratio of the
luciferase activity of each construct was calculated using a
luminometer.2.6. mRNA real time quantitative PCR
This step was done after 24-h incubation of DCs with oxLDL. The
mRNA levels were analyzed using the SYBR-GREEN reagent kits
with gene speciﬁc primers on the Applied Biosystems 7000 real
time PCR system according to the manufacturer’s instruction. Spe-
ciﬁc fragments were ampliﬁed and human glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) was also ampliﬁed to serve as
internal standard, the primer sequences are listed in Supplemen-
tary Table 1.2.7. Western blot analysis
Protein extracts were denatured and the solubilized proteins
(20 lg) were subjected to electrophoresis on 10% polyacryl
amide SDS gels, This was followed by probing with antibodies (Ab-
com) for rabbit anti-human-LOX1, scavenger receptor A (SRA),
CD36 (diluted 1:1000 in TBST), or rabbit anti-actin (diluted
1:5000 in TBST), and then by goat anti-rabbit secondary antibody
labeled with far-red-ﬂuorescent Alexa Fluor 680 dye. All signals
were detected by Odyssey (Li-cor, USA). Densitometric
analysis was performed using Quantity One (Bio-Rad) to scan the
signals.2.8. Statistical analysis
Data is presented as mean ± S.D. of at least three independent
experiments and were compared using the two-tailed paired Stu-
dent’s t-test or one-way ANOVA, a difference with a P < 0.05 was
considered to be statistically signiﬁcant.3. Results
3.1. Increased expression of miR-29a in oxLDL-treated DCs
Considering that oxLDL is a major pro-inﬂammatory factor and
auto-antigen in the development of atherosclerosis, oxLDL-stimu-
lated human primary peripheral blood DCs were chosen as the cell
model for determining the miRNAs associated with atherosclerosis.
In this study, miR-29a was found to be aberrantly expressed in
oxLDL-stimulated DCs for the ﬁrst time using TaqMan Real-time
PCR. After stimulation with oxLDL, the miR-29a levels in DCs were
increased threefold (Supplementary Fig. 1A), suggesting the role of
miR-29a in the immuno-inﬂammatory response to oxLDLs. The
miR-29a levels in DCs were then modulated. Transfection of miR-
NA-29a mimic resulted in an apparent increase in miR-29a levels
(Supplementary Fig. 1B) compared with miR-29a inhibitor and
miRNA negative transfection.
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To investigate the mechanism of miR-29a function in DCs, miR-
anda, TargetScan, and PicTar algorithms were employed to search
for putative human protein-coding gene targets of miR-29a. The
LPL gene, predicted by both TargetScan and PicTar, was further
studied as a potential target (Fig. 1). To determine if miR-29a spe-
ciﬁcally attenuates LPL expression, the level of endogenous LPL
mRNA was measured via qPCR after transfection of miR-29a mimicFig. 1. Veriﬁcation of the potential target genes (LPL) of miR-29a by luciferase report
expression was measured by real-time PCR. (B) ELISA results of LPL expression. (C) The ce
anti-miR, anti-miR-29a, pre-miR-29a, or negative control pre-miR. Data were obtained fr
30UTR plasmids only group. Data were obtained from three independent experiments. ⁄
Fig. 2. Effects of miR-29a on DCs phagocytosis and surface scavenger receptors. DCs were
24 h. CD36, LOX-1, and SRA expression were regulated after incubation with miR-29a m
respective densitometric measurement results are shown. The band density of the native
by western blot. ⁄P < 0.05 versus the ‘‘pre-neg’’ group. ⁄⁄P < 0.01 versus the ‘‘pre-neg’’ grand inhibitor into DCs. Inhibition of miR-29a expression with
miR-29a inhibitor increased LPL mRNA levels, whereas enhancing
miR-29a expression with miR-29a mimic decreased the LPL mRNA
levels relative to that in the control cells transfected with non-
speciﬁc miRNA. Consistent with the changes in mRNA levels, the
level of LPL protein was also altered by miR-29a inhibitor and
miR-29a mimic (Figs. 1A and 2B). To determine if regulation of
LPL by miR-29a is speciﬁcally mediated by the microRNA mecha-
nism, the 30-UTR of the LPL gene containing miR-29a recognitioner assay coincided with the mRNA and protein expression levels. (A) LPL mRNA
lls were cotransfected with p-LPL-UTR, pGL-3 control, and with the negative control
om at least three independent experiments. ⁄P < 0.01 compared with the pGL3-LPL–
P < 0.05 versus the ‘‘pre-neg’’ group. #P < 0.05 versus the ‘‘anti-neg’’ group.
incubated with or without miR-29a mimic/inhibitor for 6 h, and then with oxLDL for
imic and inhibitors. (A) The relative mRNA level of CD36, LOX-1, and SRA. (B) The
cells was deﬁned as the control. (C) The levels of LOX-1, CD36 and SRA were detected
oup #P < 0.05 versus the ‘‘anti-neg’’ group. ##P < 0.01 versus the ‘‘anti-neg’’ group.
Table 2
Effects of miR-29a mimcs/inhibitor and siLPLon the level of total, free and esteriﬁed







Control 500 ± 28 195 ± 16 304 ± 17
Pre-neg 534 ± 48 199 ± 27 335 ± 24
Pre-miR-29a 383 ± 43* 188 ± 18 224 ± 31*
Anti-neg 535 ± 35 201 ± 34 335 ± 2.5
Anti-miR-29a 647 ± 72 305 ± 36# 342 ± 38
Anti-miR-29a + siLPL 580 ± 44 243 ± 23 335 ± 20
Control 651 ± 58 297 ± 32 354 ± 41
si-neg 686 ± 70 324 ± 33 362 ± 36
si-LPL 493 ± 63c 218 ± 29& 276 ± 34&
Values are represented as (mean ± S.D.) mg/g, n = 3.
* P < 0.05 compared to pre-neg group.
# P < 0.05 compared to anti-neg group.
& P < 0.05 compared to si-neg group.
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The reporter gene assay showed that, compared with the pGL3-
LPL-3UTR plasmid cotransfected cells, there was a statistically sig-
niﬁcant increase and decrease in the activity of the cells cotrans-
fected with miR-29a inhibitor and miR-29a mimic (Fig. 1C,
P < 0.01). This suggests that miR-29a directly targets LPL.
3.3. miR-29a in oxLDL-induced DCs interferes with pro-inﬂammatory
cytokine production
To investigate the functional consequences of miR-29a expres-
sion in oxLDL-induced DCs, pro-inﬂammatory cytokine production
was analyzed. For this purpose, we elected to use the chemically
synthesized miR-29a inhibitor or miR-29a mimic, in which the
expression of mature miR-29a can be readily inhibited or aug-
mented. As shown in Table 1, miR-29a mimic decreased the
inﬂammatory cytokines IL-6 secretion signiﬁcantly (more than
fourfold) and miR-29a inhibitor increased its secretion (about two-
fold), meanwhile the level of TNF-a was downregulated by miR-
29a mimic slightly (40% off)and upregulated by miR-29a inhibitor
(about two-fold). This indicates that miR-29a transfection could af-
fect the inﬂammatory response of oxLDL-treated DCs.
3.4. Effects of miR-29a on the expression of surface scavenger receptors
and lipid uptake in oxLDL-stimulated DCs
Scavenger receptors family are multiligand, multifunction
receptor system which can be either internalized by endocytosis
or phagocytosis, or remain at the cell surface and mediate adhesion
or lipid transfer. Under physiological conditions, scavenger recep-
tors serve to scavenge or clean up cellular debris and other related
materials, and they play a role in host defence. In pathological
states, they mediate the recruitment, activation and transforma-
tion of macrophages and other cells which may be related to the
development of atherosclerosis [22]. To study the effects of miR-
29a on lipid uptake by DCs, associated scavenger receptors LOX1,
SRA, and CD36 were analyzed in oxLDL stimulated DCs. Interest-
ingly, miR-29a clearly enhanced the expression of SRA and a slight
increase in CD36 expression, both at the mRNA and protein level.
Meanwhile, LOX1 expression was upregulated, but no change
was observed in the LOX1 mRNA level in the oxLDL-stimulated
DCs, whereas the miR-29a inhibitor treated groups yielded the
opposite effect (Fig. 2). These results indicate that miR-29a
regulates SRA and CD36 expression at the transcriptional and
translational levels and affects LOX1 expression at the post-
transcriptional level.
Since miR-29a could regulate the expression of scavenger
receptor, we further observed whether miR-29a could effect the li-Table 1
Comparison of inﬂammatory biomarkers secreted by transfecting the miR-29a
inhibitor and mimics and siLPL.
IL-6 (ng/ml) TNF-a (ng/L)
Pre-neg 0.67 ± 0.21 64 ± 4.36
Pre-miR-29a 0.15 ± 0.01* 39.8 ± 3.62*
Anti-neg 0.66 ± 0.07 64.06 ± 7.88
Anti-miR-29a 1.28 ± 0.15# 130.51 ± 13.6#
Anti-miR-29a+siLPL 0.81 ± 0.1## 90.51 ± 9.6##
si-Neg 0.93 ± 0.08 60.42 ± 7.12
si-LPL 0.51 ± 0.06& 35.52 ± 4.8&
Concentration of inﬂammatory cytokines secreted in 24 h culture supernatants by
stimulated human primary dendritic cells from pre-miR, anti-miR, pre-neg, anti-
neg and si-neg, siLPL.
* P < 0.05 compared to pre-neg group.
# P < 0.05 compared to anti-neg group.
## P < 0.05 compared to anti-miR-29a group.
& P < 0.05 compared to si-neg group.pid composition in oxLDL-treated DC, after treatment with miR-
29a mimic/inhibitor, the levels of cholesterol in DCs were assessed
using HPLC. The levels of total and esteriﬁed cholesterol signiﬁ-
cantly decreased in the group with treated with miR-29a mimics
compared with the mimic negative group. However, no signiﬁcant
difference was observed between the inhibitor group and the neg-
ative group (Table 2).
LPL is a functional gene target involved in miR-29a-mediated li-
pid uptake and pro-inﬂammatory cytokine secretion on oxLDL-in-
duced DCs.
Given the evidence presented above regarding LPL regulation by
miR-29a at both the RNA and protein levels, and considering the
reported inﬂammatory effect of LPL, LPL could be a functionally
important target of miR-29a. To investigate the biological impor-
tance of LPL as a target of miR-29a, the LPL protein in DCs was de-
pleted using siRNA and the effects of miR-29a inhibition were
assayed. Knockdown of LPL expression by siRNA treatment efﬁ-
ciently repressed LPL mRNA and protein levels (Fig. 3A and B), de-
creased inﬂammatory cytokine secretion, downregulated lipid
uptake (Tables 1 and 2), and upregulated scavenger receptor
expression (Fig. 3C–E). These effects are similar to that of miR-
29a mimic in the oxLDL-treated DCs. Furthermore, the miR-29a
inhibitor mediated effects on the inﬂammatory response and scav-
enger receptor expression of DCs were attenuated by the inhibition
of LPL by siLPL in the oxLDL-stimulated cells (Fig. 4). The data
therefore suggest an essential role for LPL as a mediator of the bio-
logical effects of miR-29a in oxLDL-treated DCs.
4. Discussion
MiRNAs are newly identiﬁed, non-coding small RNAs, that are
involved in multiple cellular processes [23]. Over the past few
years, the vast potential of miRNAs as regulators of cardiovascular
diseases 9–15 has fully emerged and has become an intriguing tar-
get for therapeutic intervention. However, the signature of miRNA
expression and the possible roles of miRNA in atherosclerosis have
been less studied. The aim of this study is to link miRNA regulation
with lipid overload and the immuno-inﬂammatory mechanism for
atherosclerosis. The effects of miR-29a on oxLDL-stimulated DC
activation were characterized in terms of lipid uptake, endocytotic
capacity, and pro-inﬂammatory cytokine secretion to explore the
novel functional role of miR-29a in atherosclerosis immuno-
inﬂammatory mechanism.
Our previous studies [24] have shown that some miRNAs are
upregulated in oxLDL-stimulated monocytes/macrophages. In this
study, the expression of miR-29a is notably upregulated in
Fig. 3. Effects of LPL-speciﬁc knockdown on DCs. Conﬁrmation of siRNA-induced knockdown of LPL mRNA by qPCR (A) and protein level by ELISA. (B) After transfections of
the small interference RNA for LPL (siLPL) or an irrelevant control sequence (sineg) in the oxLDL-induced DCs, the expression of the surface scavenger receptors were
regulated. (C) The mRNA levels of CD36, LOX1, and SRA. (D,E) CD36, LOX1, and SRA protein levels were determined by western blot. Data are presented as mean ± S.D., and
⁄P < 0.05 compared with sineg.
Fig. 4. LPL is a functional target gene involved in miR-29a-mediated inﬂammatory and lipid uptake in oxLDL-induced DCs. The miR-29a mediated pro-inﬂammatory cytokine
secretion was attenuated in oxLDL-induced DCs via a small interference RNA for LPL (A and B), and the lipid composition was decreased. (C) The mRNA levels of CD36, LOX1,
and SRA. (D and E) CD36, LOX1 and SRA protein levels were observed by western blot. ⁄P < 0.05 compared with pure anti-miR-29a group.
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in the lipid uptake of DCs was investigated and the molecular tar-gets were revealed. On the other hand, little is known regarding
the miR-29a–LPL interaction. To our knowledge, LPL may be the
662 T. Chen et al. / FEBS Letters 585 (2011) 657–663ﬁrst identiﬁed target gene involved in the regulation of oxLDL-
stimulated DCs by miR-29a.
Understanding the connections between the miRNAs and ath-
erosclerosis has been hampered by the limited knowledge of miR-
NA target recognition. MiRNAs modulate their biological functions
via the mRNA of their multiple target genes [25]. Although their
potential gene targets can be predicted by computational analysis,
there is a need for experimental approaches to target identiﬁcation
to gain knowledge of the mechanisms and modalities of miRNA
target recognition.
LPL has emerged as a signiﬁcant contributor to the pathogenesis
of atherosclerosis. LPL belongs to the mammalian triacylglycerol li-
pase gene family, it and has been shown as a central enzyme in
overall lipid metabolism and transport. LPL inﬂuences the develop-
ment of lesions in mouse atherosclerosis models [26–28]. In addi-
tion, the mRNA expression levels of LPL in peripheral blood
mononuclear cells are strongly correlated with the mutational sta-
tus of the immunoglobulin V(H) gene. LPL is also a prognostic mar-
ker in B-cell chronic lymphocytic leukemia29. All these indicate
the pivotal role of LPL in the atherosclerosis immuno-inﬂammatory
mechanism. However, little is known about how LPL transcripts
are regulated at the post-transcriptional level, and the regulation
of LPL expression by miRNAs has not yet been described.
In the current study, computational analysis suggests that LPL
may be an miR-29a target. Moreover, miR-29a was upregulated
by oxLDL, and exposure of mature macrophages to oxLDL led to a
marked reduction of LPL activity [30]. Other research found that
miR-29a is downregulated in aggressive chronic lymphocytic leu-
kemia and B-cell chronic lymphocytic leukemia with high LPL
expression [29]. To determine whether LPL is an miR-29a target
gene in DCs, that the expression of LPL mRNA and protein in DCs
was ﬁrst conﬁrmed to be regulated by miR-29a, as determined
by both gain-of-function and loss-of-function approaches. Further-
more, luciferase reporter assay analysis veriﬁed that the LPL gene
is one of the direct targets of miR-29a. Finally, the miR-29a inhib-
itor–mediated effects on oxLDL-stimulated DCs were found to be
blocked by the siRNA treatment of LPL. These results indicate that
LPL is indeed a functional target gene of miR-29a.
In our study, oxLDL was used as a stimulus to determine the po-
tential role of miR-29a in DCs under cholesterol-laden conditions,
mimicking those often encountered during atherogenesis. Interest-
ingly, upregulation of miR-29a expression inhibits oxLDL-medi-
ated pro-inﬂammatory cytokine secretion in DCs. In contrast,
oxLDL-mediated DCs pro-inﬂammatory cytokines secretion is
exacerbated after downregulation of miR-29a expression. Previ-
ously, Qiu G et al. [31] showed that LPL suppression causes de-
creased expression of pro-inﬂammatory cytokines. Accordingly,
downregulation of LPL through miR-29a overexpression and LPL
inhibition with siRNA have similar effects. Furthermore, depletion
of LPL by siRNA transfection partly restores pro-inﬂammatory
cytokine secretion induced by miR-29a inhibition in DCs. The re-
sults suggest that miR-29a has a negative effect on oxLDL-medi-
ated pro-inﬂammatory cytokine secretion in DCs, and LPL is an
important functional target of miR-29a in this model.
Research has indicated that the pronounced oxLDL uptake
capacity of DCs is reﬂected by the expression of scavenger recep-
tors, such as lectin-like oxidized low-density lipoprotein recep-
tor-1 (LOX-1) and CD36 [32]. At the same time, after suppression
of LPL, signiﬁcantly increased expressions of lipoprotein receptors
[31] were observed. Therefore, the expression of scavenger recep-
tors was measured to demonstrate the effect of miR-29a on oxLDL-
mediated DCs lipid uptake. Transfection with the miR-29a mimic
decreased scavenger receptor expression, whereas transfection
with the miR-29a anti-sense inhibitors reduced scavenger receptor
expression. Furthermore, we explore the effect of miR-29a on the
lipid composition of DC, interestingly, increased miR-29a expres-sion was found to be also associated with an altered lipid compo-
sition and reduced percentages of cholesterol, but decreased miR-
29a expression did not obtain the opposite effect. Two reason
maybe explain the phenomenon: 1: the functional effect of miRNA
was indirectly obtained by base pairing with the 30UTRs of mRNAs,
there are many potential target gene of miR-29a, LPL was just one
of them, moreover, LPL could decrease production of cellular lipids
in macrophage, but no conﬁrmed evidence in DCs. 2: there are
many factors would inﬂuence the intracellular lipids composition
such as lipid inﬂux and efﬂux, we just observed the effect of
miR-29a on several scavenger receptors0 expression, the compli-
cated mechanisms for these effects of miR-29a on the lipid compo-
sition of DC need further study.
For the ﬁrst time, our results strongly indicate that miR-29a acts
as an important regulator of the inﬂammatory response and
scavenger receptors expression by targeting LPL. Once effective
methods of regulating miR-29a expression are achieved in a
clinical setting, it could provide a novel, speciﬁc approach to con-
trolling the formation of atherosclerosis. These novel ﬁndings
may have extensive implications for the diagnosis and therapy of
atherosclerosis.
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